Multiple myeloma can be treated by administration of irinotecan combined with revimid. The present invention includes methods of treating multiple myeloma by administering the combination of irinotecan and revimid, as well as pharmaceutical kits.

The present invention relates to a method for treating locally advanced or metastatic breast cancer in a patient who demonstrated failure of prior treatment with an anthracycline, a taxane and a fluoropyrimidine, which comprises administering a therapeutically effective amount of irinotecan.

The present invention relates to a method for preventing irinotecan-induced or camptothecin-induced or camptothecin-analog-induced diarrhea by administering an effective amount of octreotide. In particular the invention concerns new methods, combination formulations and kits to prevent late diarrhea caused by irinotecan or camptothecin, or camptothecin-analog administration.

This invention discloses and claims novel intermediates and procedures for the synthesis of camptothecin derivatives, such as irinotecan, and other compounds related to the synthesis of CPT-11. Related procedures and compounds are also disclosed, such as a novel method of making mappicine.

PCT No. PCT/US96/04163 Sec. 371 Date Oct. 2, 1997 Sec. 102(e) Date Oct. 2, 1997 PCT Filed Apr. 1, 1996 PCT Pub. No. WO96/31513 PCT Pub. Date Oct. 10, 1996This invention relates to intermediates and processes for the synthesis of camtothecin derivatives, such as irinotecan. Related procedures and compounds are disclosed, such as a method of making mappicine.

The present invention provides a method for preventing or decreasing diarrhea associated with irinotecan administration comprising the administration of tamoxifen at least two cell cycles prior to irinotecan administration.

The present invention provides a method for preventing or decreasing diarrhea associated with irinotecan administration comprising the administration of tamoxifen at least two cell cycles prior to irinotecan administration.

The present invention provides a method for preventing or decreasing diarrhea associated with irinotecan administration comprising the administration of tamoxifen at least two cell cycles prior to irinotecan administration.

The present invention provides a method for preventing or decreasing diarrhea associated with irinotecan administration comprising the administration of tamoxifen at least two cell cycles prior to irinotecan administration.